← Oncology Institute, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net loss | ($441k) | ($10.9m) | $152k | ($83.1m) | ($64.7m) | ($60.6m) | — | |
| Depreciation and amortization | $3.2m | $3.3m | $4.4m | $5.9m | $6.3m | $6.9m | $6.8m | |
| Amortization of debt issuance costs and debt discount | $60k | $53k | $2.4m | $6.2m | $6.3m | $8.4m | — | |
| Deferred taxes | ($1.3m) | ($1.2m) | ($263k) | ($76k) | $0 | ($32k) | — | |
| Share-based compensation | $151k | $24.5m | $27.7m | $17.8m | $11.2m | $4.6m | $5.1m | |
| Accounts receivable | ($6.8m) | ($2.2m) | ($20.3m) | ($4.6m) | ($6.0m) | ($12.3m) | ($10.8m) | |
| Other receivables | $5k | ($792k) | $620k | $66k | $205k | ($274k) | — | |
| Inventories | ($465k) | ($1.8m) | ($1.7m) | ($4.4m) | $3.6m | ($6.8m) | ($4.2m) | |
| Accounts payable | $3.8m | $2.9m | ($6.2m) | $5.1m | $9.2m | $19.6m | $25.3m | |
| Purchases of property and equipment included in accounts payable | $1.2m | $2.8m | $0 | $182k | $680k | $441k | ($3.6m) | |
| Accrued expenses and other current liabilities | $48k | ($3.1m) | $2.3m | $3.4m | $9.5m | ($448k) | — | |
| Other assets | ($25k) | ($198k) | ($157k) | ($84k) | ($28k) | ($17k) | — | |
| Net cash and cash equivalents used in operating activities | ($583k) |
($32.7m)
-5510.04%
|
($61.8m)
-88.97%
|
($36.3m)
+41.20%
|
($26.5m)
+26.92%
|
($24.6m)
+7.35%
|
$328k
+101.33%
|
|
| Loss on disposal of property and equipment | $60k | $0 | $21k | ($30k) | $271k | $0 | — | |
| Purchases of property and equipment | ($1.2m) | ($2.8m) | ($5.5m) | ($4.6m) | ($3.8m) | ($3.2m) | ($3.6m) | |
| Unrealized (gain) loss on investments | — | $0 | $378k | ($249k) | ($133k) | $0 | $0 | |
| Sales of marketable securities/investments | — | — | $0 | $81.3m | $50.0m | $0 | — | |
| Net cash and cash equivalents provided by (used in) investing activities | ($230.0m) | ($12.2m) | ($131.6m) | $62.6m | $46.2m | ($3.1m) | — | |
| Principal payments on long-term debt | ($281k) | ($7.2m) | $0 | — | $0 | ($20.0m) | — | |
| Common stock issued for warrants exercised | — | — | — | — | $0 | $517k | — | |
| Common stock issued for options exercised | $50k | $0 | $858k | $126k | $75k | $2.8m | — | |
| Net cash and cash equivalents provided by (used in) financing activities | $231.5m |
$154.0m
-33.47%
|
$92.2m
-40.13%
|
($6.8m)
-107.43%
|
($3.5m)
+49.00%
|
$11.6m
+430.96%
|
— | |
| Net (decrease) increase in cash and cash equivalents | $892k | $109.2m | ($101.2m) | $19.5m | $16.2m | ($16.1m) | — | |
| Cash and cash equivalents at beginning of period | $917k | $115.2m | $14.0m | $33.5m | $49.7m | $33.6m | — | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Write-off of assets from clinical trials segment | — | — | — | — | — | $2.4m | — | |
| Change in fair value of liability classified warrants | $0 | ($3.7m) | ($1.8m) | $286k | ($619k) | $247k | — | |
| Change in fair value of liability classified conversion option derivatives | $0 | ($24.9m) | ($24.2m) | ($878k) | ($2.7m) | $12.2m | — | |
| Accretion of discount on investment securities | — | $0 | ($1.0m) | ($2.6m) | ($500k) | $0 | — | |
| Prepaid expenses | ($152k) | ($9.1m) | $4.3m | $3.1m | $1.2m | $2.0m | — | |
| Change in operating leases | — | $0 | ($3.8m) | ($5.3m) | ($2.8m) | ($452k) | — | |
| Other non-current liabilities | $3k | $809k | ($1.2m) | ($443k) | ($203k) | ($11k) | — | |
| Proceeds from asset disposition | — | — | — | — | $0 | $126k | — | |
| Proceeds from private placement, net of offering costs | $5.6m | — | — | — | $0 | $15.4m | — | |
| Proceeds from at-the-market offering, net of offering costs | — | — | — | $126k | $75k | $13.8m | — | |
| Proceeds from employee stock purchase plan | — | — | — | — | $0 | $151k | — | |
| Payments made for financing of insurance payments | $0 | ($409k) | ($5.0m) | ($3.3m) | ($1.2m) | ($991k) | — | |
| Payment of deferred consideration liability for acquisition | $0 | ($50k) | ($509k) | ($2.6m) | ($2.4m) | ($50k) | — | |
| Principal payments on financing leases | — | ($32k) | ($58k) | ($101k) | ($39k) | ($37k) | — | |
| Interest | $227k | $275k | $224k | $4.5m | $4.5m | $3.9m | $3.5m | |
| Principal exchange of convertible note for preferred stock | — | — | — | — | $0 | $4.1m | — | |
| Right-of-use assets in connection with operation lease modifications | — | — | — | — | $1.4m | $1.6m | — | |
| Financed insurance premiums | — | — | $0 | $1.3m | $844k | $794k | — |